Artificial intelligence may reduce false positives in breast cancer screening

AI tool could become part of diagnostic protocol More at https://www.nsf.gov/discoveries/disc_summ.jsp?cntn_id=303695&WT.mc_id=USNSF_1 This is a Research News item.
Source: NSF Discoveries - Category: Science Source Type: research

Related Links:

In this study, they found these drugs can kill senescent cells from cultures of human fat tissue. The tissue was donated by individuals with obesity who were known to have metabolic troubles. Without treatment, the human fat tissues induced metabolic problems in immune-deficient mice. After treatment with dasatinib and quercetin, the harmful effects of the fat tissue were almost eliminated. Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.PMID:34862246 | DOI:10.1158/1078-0432.CCR-21-3231
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study characterized breast cancer treatment disruptions in schizophrenia patients and sought to identify and resolve correctable predictors of those disruptions.MATERIALS AND METHODS: A retrospective cohort study was conducted on 55 primary breast cancer patients diagnosed with schizophrenia and treated for breast cancer. We evaluated the characteristics of the breast cancer patients with schizophrenia compared to those of 610 breast cancer patients without schizophrenia.RESULTS: Compared to the control group, the schizophrenia group had significantly advanced T and N factors and disease stage. Significantly fewer pat...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.PMID:34862246 | DOI:10.1158/1078-0432.CCR-21-3231
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study characterized breast cancer treatment disruptions in schizophrenia patients and sought to identify and resolve correctable predictors of those disruptions.MATERIALS AND METHODS: A retrospective cohort study was conducted on 55 primary breast cancer patients diagnosed with schizophrenia and treated for breast cancer. We evaluated the characteristics of the breast cancer patients with schizophrenia compared to those of 610 breast cancer patients without schizophrenia.RESULTS: Compared to the control group, the schizophrenia group had significantly advanced T and N factors and disease stage. Significantly fewer pat...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Surgery. 2021 Oct 22:S0039-6060(21)01013-8. doi: 10.1016/j.surg.2021.10.033. Online ahead of print.ABSTRACTBACKGROUND: During the COVID-19 pandemic, guidelines recommended that breast cancer centers delay estrogen receptor-positive breast cancer surgeries with neoadjuvant endocrine therapy. We aimed to evaluate pathologic upstaging of breast cancer patients affected by these guidelines.METHODS: Female patients with stage I/II breast cancer receiving neoadjuvant endocrine therapy were prospectively identified and were matched to a historical cohort of stage I/II estrogen receptor-positive breast cancer patients treated with...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.PMID:34862246 | DOI:10.1158/1078-0432.CCR-21-3231
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research
Phytother Res. 2021 Dec 4. doi: 10.1002/ptr.7345. Online ahead of print.ABSTRACTDocetaxel (DTX) is used against breast cancer despite its side effects such as toxicity and immunosuppression. Here we investigated the cytotoxic and immunomodulatory effects of the ethanol solution extract of propolis (EEP) in combination with DTX on MCF-7 breast cancer cells and on women's monocyte. The cytotoxic potential of EEP + DTX was assessed by MTT assay and the type of tumor cell death was evaluated by flow cytometry. The effects of EEP + DTX on the migration and invasion of MCF-7 cells were analyzed. Cytokine production by monocytes ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
CONCLUSION: Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.PMID:34862246 | DOI:10.1158/1078-0432.CCR-21-3231
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Ten percent of women developed BC after EOC. The incidence of BC following EOC in BRCA carriers increases over time, and surveillance is recommended given their enhanced survival of EOC. Timely genetic testing for women with EOC is imperative to better triage BC screening resources and treatment.PMID:34862065 | DOI:10.1016/j.ygyno.2021.10.077
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Science